Fredun Pharma

Which are the latest news on Fredun Pharma?

Why is Fredun Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Fredun Pharmaceuticals Ltd's stock price is 1,474.10, down 0.95% after two consecutive days of decline. Despite strong long-term performance, recent trends indicate reduced investor interest and short-term losses.

As of 05-Sep, Fredun Pharmaceuticals Ltd's stock price is currently at 1,474.10, reflecting a decrease of 14.1 points or 0.95%. The stock has been underperforming in the short term, having fallen for the last two consecutive days, resulting in a total decline of 2.37% during this period. Despite opening with a gain of 2.44% today and reaching an intraday high of Rs 1,524.5, the overall performance has been negative, as it has underperformed its sector by 0.74%.<BR><BR>Investor participation has also declined, with the delivery volume dropping by 41.01% compared to the 5-day average, indicating reduced trading interest. While the stock has shown strong performance over longer periods, such as a 180.19% increase year-to-date and a remarkable 1,071.59% rise over the past five years, the recent trend suggests a short-term decline influenced by falling investor engagement and consecutive losses.

Who are in the management team of Fredun Pharma?

The management team of Fredun Pharma includes Daulat N Medhora (Chairperson & Joint Managing Director), Nariman B Medhora (Executive Director), Fredun N Medhora (Managing Director & CFO), along with independent directors Aspi N Raimalwala and Rohinton Kanga, Company Secretary Jinkal Shah, and Additional Director Daisy Dsouza.

The management team of Fredun Pharma includes the following individuals:<BR><BR>1. **Daulat N Medhora** - Chairperson & Joint Managing Director<BR>2. **Nariman B Medhora** - Executive Director<BR>3. **Aspi N Raimalwala** - Non-Executive & Independent Director<BR>4. **Fredun N Medhora** - Managing Director & Chief Financial Officer<BR>5. **Rohinton Kanga** - Non-Executive & Independent Director<BR>6. **Jinkal Shah** - Company Secretary & Compliance Officer<BR>7. **Daisy Dsouza** - Additional Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Fredun Pharma do?

Fredun Pharmaceuticals Ltd, a micro-cap company established in 1987, operates in the Pharmaceuticals & Biotechnology sector, reporting net sales of 228 Cr and a net profit of 13 Cr for June 2026. The company has a market cap of INR 2,418 Cr and key metrics include a P/E ratio of 55.00 and a return on equity of 15.95%.

Overview:<BR>Fredun Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Incorporated in 1987 as a Private Limited company, Fredun Pharmaceuticals Limited became a Public limited company in March 1994. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 228 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 13 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 2,418 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 55.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.03% <BR>Debt-Equity: 0.56 <BR>Return on Equity: 15.95% <BR>Price to Book: 8.74<BR><BR>Contact Details:<BR>Address: 26 Manoj Industrial Premises, G D Ambedkar Marg Wadala Mumbai Maharashtra : 400031 <BR>Tel: 91-22-40318111 <BR>Email: business@fredungroup.com <BR>Website: http://www.fredungroup.com

Who are the peers of the Fredun Pharma?

Fredun Pharma's peers include Advanced Enzyme, Ind-Swift Labs, Solara Active, Dishman Carbogen, Hikal, Panacea Biotec, Indoco Remedies, Venus Remedies, and Beta Drugs Ltd. Fredun Pharma shows excellent growth and a 1-year return of 279.00%, outperforming its peers, while management risk varies across the group.

Peers: The peers of Fredun Pharma are Advanced Enzyme, Ind-Swift Labs., Solara Active, Dishman Carbogen, Hikal, Panacea Biotec, Indoco Remedies, Venus Remedies, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Advanced Enzyme and Beta Drugs Ltd, while Average management risk is found at Fredun Pharma, Hikal, Indoco Remedies, and Venus Remedies. Below Average management risk is present at Ind-Swift Labs., Solara Active, Dishman Carbogen, and Panacea Biotec. Growth is Excellent at Fredun Pharma, Good at Dishman Carbogen and Venus Remedies, Below Average at Advanced Enzyme, Ind-Swift Labs., Solara Active, Hikal, Panacea Biotec, and Indoco Remedies, and Average at Beta Drugs Ltd. Capital Structure is Excellent at Advanced Enzyme and Beta Drugs Ltd, Below Average at Fredun Pharma, Hikal, Solara Active, Dishman Carbogen, Panacea Biotec, Indoco Remedies, and Venus Remedies, and Average at Ind-Swift Labs.<BR><BR>Return Snapshot: Ind-Swift Labs. has the highest 1-year return at 278.73%, while Dishman Carbogen has the lowest at -32.34%. Fredun Pharma's 1-year return is 279.00%, which is higher than both of these peers. Additionally, Hikal and Panacea Biotec have negative six-month returns.

How big is Fredun Pharma?

As of 31st August, Fredun Pharmaceuticals Ltd has a market capitalization of 2,418.00 Cr, with net sales of 747.53 Cr and a net profit of 43.82 Cr reported in the latest four quarters.

As of 31st August, Fredun Pharmaceuticals Ltd has a market capitalization of 2,418.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Fredun Pharmaceuticals reported net sales of 747.53 Cr and a net profit of 43.82 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with shareholder's funds amounting to 278.11 Cr and total assets of 642.08 Cr.

Should I buy, sell or hold Fredun Pharmaceuticals Ltd?

Are Fredun Pharmaceuticals Ltd latest results good or bad?

Fredun Pharmaceuticals Ltd's latest results are very good, with a 93.94% year-on-year net profit growth to ₹13.13 crores and a 90.45% revenue increase to ₹228.25 crores, marking the highest quarterly sales in the company's history. However, rising interest costs and increasing debt levels should be monitored as potential challenges.

Fredun Pharmaceuticals Ltd's latest results are quite impressive, indicating strong performance. In Q1 FY27, the company reported a net profit of ₹13.13 crores, which reflects a remarkable year-on-year growth of 93.94%. Additionally, revenue saw a substantial increase of 90.45% compared to the same quarter last year, reaching ₹228.25 crores. This marks the highest quarterly sales figure in the company's history and demonstrates robust operational momentum, as it is the seventh consecutive quarter of revenue growth.<BR><BR>The operating margin improved to 14.37%, and the return on equity (ROE) stands at a healthy 15.95%, showcasing strong capital efficiency. The stock has also performed exceptionally well, with a staggering 265.09% return over the past year, significantly outperforming the broader pharmaceuticals sector.<BR><BR>Overall, the results can be categorized as very good, reflecting strong demand dynamics and effective market strategies. However, it is important to monitor the rising interest costs and the company's increasing debt levels, which could pose challenges moving forward.

When is the next results date for Fredun Pharmaceuticals Ltd?

The next results date for Fredun Pharmaceuticals Ltd is August 5, 2026.

The next results date for Fredun Pharmaceuticals Ltd is scheduled for August 5, 2026.

How has been the historical performance of Fredun Pharma?

Fredun Pharma has shown steady growth, with net sales of 456.27 crore and a profit after tax of 19.74 crore for the fiscal year ending March 2025. The company's total assets increased to 307.60 crore, reflecting a solid financial position and consistent growth in sales and profits.

Answer:<BR>The historical performance of Fredun Pharma reflects a steady growth trajectory in various financial metrics.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Fredun Pharma reported net sales of 456.27 crore, resulting in a total operating income of the same amount. The total expenditure, excluding depreciation, was 401.36 crore, leading to an operating profit (PBDIT) of 54.91 crore, which corresponds to an operating profit margin of 12.16%. The profit before tax stood at 27.49 crore, with a profit after tax of 19.74 crore, yielding a PAT margin of 4.37%. The earnings per share (EPS) were reported at 41.82, while the diluted EPS was slightly higher at 44.83. On the balance sheet, total assets increased to 307.60 crore in March 2024 from 257.28 crore in the previous year, with total liabilities also rising to 105.51 crore. The book value per share adjusted to 255.15, indicating a solid increase from prior years. Cash flow analysis shows a net cash outflow of 2.00 crore for March 2024, with cash and cash equivalents closing at 1.00 crore. Overall, Fredun Pharma demonstrates a robust financial position with consistent growth in sales, profits, and asset values over the years.

Is Fredun Pharma overvalued or undervalued?

As of November 10, 2025, Fredun Pharma is considered overvalued with a PE ratio of 26.61, an EV to EBITDA of 13.28, and a ROE of 20.44%, despite outperforming the Sensex with a year-to-date return of 120.94%.

As of 10 November 2025, Fredun Pharma's valuation grade has moved from attractive to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 26.61, an EV to EBITDA of 13.28, and a ROE of 20.44%. <BR><BR>In comparison to its peers, Fredun Pharma's PE ratio is lower than Sun Pharma's 35.15 but significantly higher than Cipla's 22.45, suggesting that while it is less expensive than some competitors, it remains on the higher end of the spectrum. Additionally, the company's recent stock performance has outpaced the Sensex, with a year-to-date return of 120.94% compared to the Sensex's 6.91%, reinforcing the notion of overvaluation amidst strong market enthusiasm.

Who are the top shareholders of the Fredun Pharma?

The top shareholders of Fredun Pharma are Daulat Nariman Medhora with 29.88%, followed by Nikhil Kishorchandra Vora at 6.38%. Individual investors collectively own 44.5%, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Fredun Pharma include Daulat Nariman Medhora, who holds the largest stake at 29.88%. Following him, the highest public shareholder is Nikhil Kishorchandra Vora, with a holding of 6.38%. Additionally, individual investors collectively own 44.5% of the company. There are no institutional holdings or pledged promoter shares reported.

What is the technical trend for Fredun Pharma?

As of April 15, 2025, Fredun Pharma's technical trend is mildly bearish, with weekly indicators showing some positive momentum while daily moving averages and monthly indicators remain bearish.

As of 15 April 2025, the technical trend for Fredun Pharma has changed from bearish to mildly bearish. The weekly MACD and KST are both mildly bullish, suggesting some positive momentum, while the monthly indicators remain bearish. The daily moving averages indicate a mildly bearish stance, which is a counterpoint to the weekly signals. The Bollinger Bands show a mildly bullish trend on the weekly timeframe but are bearish on the monthly. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this outlook.

Has Fredun Pharma declared dividend?

Yes, Fredun Pharmaceuticals Ltd has declared a 7% dividend, with an ex-date of September 23, 2024. While recent total returns have been negative over shorter periods, the company has shown significant positive returns over the longer term.

Fredun Pharmaceuticals Ltd has declared a 7% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 7%<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.1%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -5.58%, with a dividend return of 0%, resulting in a total return of -5.58%.<BR><BR>Over the past year, the price return was -8.86%, the dividend return was 0.09%, leading to a total return of -8.77%.<BR><BR>In the 2-year period, the price return was -12.9%, with a dividend return of 0.16%, culminating in a total return of -12.74%.<BR><BR>For the 3-year period, the price return was -14.32%, the dividend return was 0.18%, resulting in a total return of -14.14%.<BR><BR>In the last 4 years, the price return was 71.47%, with a dividend return of 0.51%, giving a total return of 71.98%.<BR><BR>Over the past 5 years, the price return was 296.33%, and the dividend return was 1.12%, leading to a total return of 297.45%.<BR><BR>Overall, while Fredun Pharma has declared a dividend, the total returns over various periods show a mix of negative returns in the shorter terms and significant positive returns in the longer terms, indicating volatility and potential recovery in the company's performance.